02.07. Área de Salud VII Murcia Este

Ergonomic Risk in Total Hip Arthroplasty: Approach-Specific Postural Loads and Position-Swap Effects During Cup Preparation

2026-04-01T00:00:00Z

Ergonomic Risk in Total Hip Arthroplasty: Approach-Specific Postural Loads and Position-Swap Effects During Cup Preparation Marín-Martínez, Carmelo; Mantilla-de-los-Ríos-García, José-Emilio; Galián-Muñoz, Elena; Sánchez-Robles, Marina; León-Muñoz, Vicente-Jesús; Murcia-Asensio, Antonio; Moreno-Cascales, Matilde; Lajara-Marco, Francisco

Implementation of quantitative HBsAg testing in clinical microbiology laboratories in Spain: Results from a national GEHEP-SEIMC survey

2026-08-01T00:00:00Z

Implementation of quantitative HBsAg testing in clinical microbiology laboratories in Spain: Results from a national GEHEP-SEIMC survey Chaves-Blanco, Lucía; Illescas-López, Marta; Fuentes, Ana; Carracedo, Raquel; Delgado-Iribarren, Alberto; Vázquez-Blanquino, Alberto; Blázquez, Ana-María; Saez, Ruth; Miqueleiz, Ana; de-los-Reyes-Vidal, María; Tosco, Tomas; Gómez, César; Moldes, Luz; Calvo, Noelia; Pérez-Rodríguez, Lucía; Trigo, Matilde; Dolores-Ocete, María; Alcaraz, María-Jesús; Asuncion-Iborra, María; García, Julio; Joaquin-Blas, José; María-Vallejo, Aldara; Alberola-Romano, Ana; Illescas, Soledad; Rodríguez, Juan-Carlos; Alonso, Roberto; Cámara, Margarita; Dolores-Navarro, María; Luisa-Núñez, María; del-Amor-Espín, María-Jesús; Beteta, Alicia; Cascales-Alcolea, Eva; Miguel-Soria, Luis; Gacinuno, Sonsoles; Sandoval, Marta; Cortizo, Sandra; Ordóñez, Patricia; Liendo, Paloma; Pérez, Mercedes; Álvarez-Arguelles, Marta; García, Fernando; Rodríguez, Inmaculada; Gómez, Carmen; Elorduy, Luis; Hernández-Febles, Melisa; González-Praetorius, Alejandro; Liebana, Carmen; Lourdes-Molina, María; Salicio, Yolanda; Macho, Mikele; Becerril, Berta; Franco-Álvarez, Francisco; Falcés-Romero, Iker; Algarete, Sonia; Jose-Gude, María; Pablo, Daniel; Magdalena-Lara, María; Montiel, Natalia; Freyre, Carolina; Galán, Juan-Carlos; Pérez, Ana-Belén; Lorenzo, Belén; Fraile, Pablo; Sánchez-Yebra, Waldo; Viciana, Isabel; Sampedro, Antonio; del-Carmen-Lozano, María; Domínguez-Castano, Ana; Ramírez, Encarnación; Beltran, Inocencio; Martin, Teresa; Puerta, Antonio; Tajada, Pilar; Panes, Paula; Martín, Adrián; Hurtado, Juan-Carlos; López-Braos, Javier; Arjona, Francisco; Miro, Elisenda; Ruiz, Montserrat; Ramírez, Mercedes; Gil-Fortuno, María; González-Pellicer, Rosa; Acedo, Juan-Manuel; Anel-Pedroche, Jorge; Infante-Urrios, Ana; Domínguez, Victoria; Aran-Toha, Guillermo; Mrtinez-Macias, Olalla; Orta-Mira, Nieves; Torres-Sopena, Luis; Cantudo, Purificación; Araceli-Hernández, María; Arroyo-Serrano, Teresa; Rando, Ariadna; Garrido, Marta; Fernández, Gema; de-Salazar, Adolfo; Aguilera, Antonio; García, Federico

Effect of Non-nucleoside Resistance-Associated Mutations on the Effectiveness of Long-Acting Cabotegravir plus Rilpivirine Therapy: Insights From the Real-World RELATIVITY Cohort

2026-07-01T00:00:00Z

Effect of Non-nucleoside Resistance-Associated Mutations on the Effectiveness of Long-Acting Cabotegravir plus Rilpivirine Therapy: Insights From the Real-World RELATIVITY Cohort Rial-Crestelo, David; Llenas-García, Jara; Hidalgo-Tenorio, Carmen; Troya-García, Jesús; Galindo-Puerto, María-José; Alemán-Valls, María-Remedios; Torralba-González-de-Suso, Miguel; Buzon, Luis; Díaz-de-Santiago, Alberto; Rodríguez, Adrián; Calzado-Isbert, Sonia; Aguilera-García, María; Morano-Amado, Luis-Enrique; Vinuesa-García, David; Bernal-Morell, Enrique; Martínez-Álvarez, Rosa-María; Cabello-Clotet, Noemi; Fernández, Analuz; Montero-Hernández, María-del-Carmen; Díez-Romero, Cristina; Calderon-Hernaiz, Ruth; Pérez-Martínez, Desiree; Gisbert-Pérez, Laura; Arenas-García, Víctor; Escrich, Cristina; Farinas-Álvarez, María-del-Carmen; Lucas-Dato, Ana; Losa-García, Juan-Emilio; Pernas-Pardavila, Hadrian; Gainzarain, Juan-Carlos; Estébanez, Miriam; Barragán-Gallo, Patricia; Clavero-Olmos, Marta; Egido-Murciano, Miguel-Vicente; Ferrero-Beneitez, Óscar-Luis; Pedrero-Tome, Roberto; Cabello-Úbeda, Alfonso; Martin-Carbonero, Luz BACKGROUND: The impact of pre-existing non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations (RAMs) on the effectiveness of long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) remains poorly defined, particularly for mutations like K103N that do not directly compromise RPV susceptibility (non-RPV NNRTI RAMs). METHODS: This observational substudy within the Spanish RELATIVITY cohort included people with HIV (PWH) who switched to CAB + RPV LA before 2025. We compared virologic outcomes between those with non-RPV NNRTI RAMs and a reference group without NNRTI/INSTI-RAMs or prior NNRTI-based virologic failure (VF). An additional subgroup with RPV-associated RAMs was also analyzed. Confirmed virologic failure (CVF) was defined as 2 consecutive viral loads ? 200 copies/mL or 1 ?500 copies/mL. RESULTS: Among 1358 participants, 83 (6.1%) harbored non-RPV NNRTI RAMs (47 with K103N) and 1247 served as the reference group. After a median follow-up of 16.7 months, CVF rates were similar between the non-RPV NNRTI RAMs group and the reference group (1.2% vs 0.8%; HR: 1.39; 95% CI: 0.18-10.84; P = .755). No significant differences were observed in viral blips (6% vs 8.2%; P = .481). Notably, in the subgroup of 28 participants with RPV-associated RAMs (including 5 with high-level resistance), no CVFs occurred over a median of 13.5 months. CONCLUSIONS: In a real-world setting, CAB + RPV LA demonstrated high effectiveness in PWH with pre-existing NNRTI RAMs that do not compromise RPV susceptibility, including K103N. While no failures were seen in those with RPV-associated RAMs, these results should be interpreted with caution due to the small sample size.

CABO-CHANCE study: A real-life world study of Cabotegravir plus Rilpivirine long-acting intramuscular in ART-experienced people with HIV.

2026-07-01T00:00:00Z

CABO-CHANCE study: A real-life world study of Cabotegravir plus Rilpivirine long-acting intramuscular in ART-experienced people with HIV. Hidalgo-Tenorio, Carmen; Aguilera-García, María; de-los-Santos, Ignacio; Ruiz-Sancho, A-; Rivero, A; López-Lirola, A; Omar, M; Romero, A; Bernal-Morell, Enrique; Martínez, O; López, T; Sorni, P; García-Ocana, P; Moreno, S; Sanjoaquin, I; Blanco, J-R; García, C BACKGROUND: This study of people with HIV (PWH) receiving CAB + RPV LAI evaluated its effectiveness, safety, and impact on inflammatory markers, body fat/lean mass distributions, quality of life, sleep, health satisfaction, and stigma experience over 1 y. METHODS: A prospective, longitudinal, multicentre study was conducted in 15 hospitals and enrolled between June 2023 and January 2024. It included virologically suppressed PWH (HIV-1 RNA <50 c/mL for ?6 months) switched from oral antiretroviral therapy to CAB + RPV LAI. Anthropometrics, CD4/CD8 counts, viral load, creatinine clearance, lipid levels, and inflammatory markers were recorded at baseline and 12, 28, 52 weeks. Patient-reported outcomes were gathered using the WHOQOL-HIV-BREF, HIV stigma scale for use in Spain, Pittsburgh Sleep Quality Index, and questionnaires on health satisfaction and adverse events. A subpopulation underwent to whole-body dual energy X-ray absorptiometer (DEXA). RESULTS: Among 269 PWH (mean age 45.6 y; 89.2% male), 240 completed 52-week follow-up, 14 (5.2%) were lost to follow-up, six (2.2%) withdrew consent, 5 (1.9%) were discontinued for adverse events, and one (0.4%) had virological failure (week 12). Snapshot effectiveness was 88.8% (intention-to-treat) and 97.5% (per-protocol). No oral bridging was required. CD4/CD8 ratio (P = 0.0001) and creatinine clearance (P = 0.0001) increased, d-dimer decreased at week 12 (P = 0.001), and BMI modestly increased (P = 0.046). No changes in total/regional fat or lean mass by DEXA (n = 56). Stigma (P = 0.029) and adverse events (P = 0.001) improved. CONCLUSIONS: In this real-world cohort, CAB + RPV LAI was highly effective and safe, was associated with a possible favourable immunologic response, a transient reduction in inflammation, and reduced perceived stigma over 1 y.